Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
C4 Therapeutics presents cemsidomide biomarker data at IMS Annual MeetingSep 25Clinical readoutC4 Therapeutics, Inc.cemsidomide
C4 Therapeutics reports Q2 2026 results, cemsidomide trials on track for 2027 dataAug 11Quarterly updateC4 Therapeutics, Inc.cemsidomide